Core Viewpoint - OPKO Health and Entera Bio have entered into a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for treating obesity and metabolic disorders, with plans to file an Investigational New Drug application with the FDA later this year [1][2]. Group 1: Collaboration Details - OPKO will hold a 60% ownership interest in the program, while Entera will hold 40%, and they will share development costs accordingly [2]. - OPKO purchased 3,685,226 ordinary shares of Entera at $2.17 per share to fund Entera's share of costs through Phase 1 of the development program [2]. - Entera has the option to continue funding its share post-Phase 1 to maintain its ownership interest; if it opts out, it will retain a 15% interest in the program [2]. Group 2: Product Information - The program combines OPKO's long-acting oxyntomodulin analog (OPK-88006) with Entera's N-Tab™ technology, which has shown favorable pharmacodynamic and pharmacokinetic data [1][5]. - Oxyntomodulin is a naturally occurring peptide hormone that suppresses appetite and induces weight loss, with additional cardioprotective and anti-fibrotic properties [5]. Group 3: Company Backgrounds - Entera Bio focuses on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology, with a pipeline that includes five oral peptide programs [6]. - OPKO Health is a multinational biopharmaceutical and diagnostics company aiming to establish leading positions in rapidly growing markets through its discovery and commercialization expertise [7].
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders